Indeed, the preferential expansion of T cells specific to viral or tumor antigens, revealed as increased frequencies of CD8+ T cells binding the LCMV-specific or tumor-specific MHCI-tetramers in mouse models of chronic infections and cancer [7–9,11], has indicated that only antigen-stimulated CD8+ T cells form better effectors. Here, CD8A is linked to cancer.